Ssu-Chuan Lai

Director, President and Chief Executive Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer), VitaSpring Biomedical Co. Ltd.

Former. First published here October 28, 2026; built from records as of October 28, 2026.

VitaSpring Biomedical Co. Ltd. named Jing-Zhou Chen to succeed Ssu-Chuan Lai, effective September 7, 2026.²

Seats

The seat in the record

Company	Title as filed	Standing	Filings
VitaSpring Biomedical Co. Ltd. (VSBC) Services-Commercial Physical & Biological Research	Director, President and Chief Executive Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)	Former	2

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

September 7, 2026effective
VitaSpring Biomedical Co. Ltd. named Jing-Zhou Chen to succeed Ssu-Chuan Lai, effective September 7, 2026. Profile of Jing-Zhou Chen.
Ssu-Chuan Lai, as the sole director then in office, appointed Jing-Zhou Chen as the Company’s Chief Executive Officer, President, Chief Financial Officer, and Secretary, to serve at the pleasure of the Board and until his successor is duly […]
[2] Filing by VitaSpring Biomedical Co. Ltd., filed with the SEC on September 10, 2026. Read the filing. The record at CFO Tribune.
June 17, 202610-K filed
Ssu-Chuan Lai signed the annual report of VitaSpring Biomedical Co. Ltd. on Form 10-K as Director, President and Chief Executive Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer), filed June 17, 2026.
/s/ Ssu-Chuan Lai Ssu-Chuan Lai Director, President and Chief Executive Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)
[1] Annual report on Form 10-K by VitaSpring Biomedical Co. Ltd., filed with the SEC on June 17, 2026. Read the filing. The record at CFO Tribune.

Sources

Annual report on Form 10-K, VitaSpring Biomedical Co. Ltd.. U.S. Securities and Exchange Commission, EDGAR, filed June 17, 2026. sec.gov; record.
Current report filed with the SEC, VitaSpring Biomedical Co. Ltd.. U.S. Securities and Exchange Commission, EDGAR, filed September 10, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Ssu-Chuan Lai wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.